HUMA Humacyte Inc
Company Analysis
Latest News
Humacyte's FDA Nod Points to a Dialysis Blockbuster — But Can a $200 Million Company Afford the Race?
Shares of Humacyte surged 9.5% to $0.73 after the company confirmed that recent FDA discussions support a November 2026 supplemental filing to sell its...
🟢 Humacyte is trading 9.51% up today after FDA discussions support November 2026 dialysis-access filing
Humacyte is trading at $0.73, up +9.51% after confirming FDA discussions support a supplemental BLA filing in November 2026 for ATEV dialysis access. -...
🟢 Humacyte is trading 5% up today after FDA discussions confirmed November dialysis-access BLA filing
Humacyte is trading 5.26% up now at $0.68 after announcing on August 24, 2026, that FDA discussions confirmed plans to file a supplemental BLA for ATEV...
🟢 Humacyte is trading 5.3% up in pre-market; catalyst remains unclear
Humacyte is trading 5.3% up at $0.68 after rising from the August 21, 2026 close of $0.64, with the immediate cause unclear; no confirmed company-specific...
🟢 Humacyte is trading 5.3% up today in after-hours trading with no confirmed catalyst
Humacyte is trading 5.3% up at $0.68 in after-hours trading, with no fresh company-specific announcement clearly explaining the increase. - It closed at $0.64...
🔴 Humacyte is trading 5.3% down today amid possible profit-taking and cash-burn concerns
Humacyte is trading at $0.65, down -5.31%, while underperforming a stronger market and biotech sector, potentially reflecting profit-taking or concerns over...
Humacyte Director buys 30,000 shares, following superior Phase 3 trial data
Humacyte published one-year results from its V007 Phase 3 trial in The Lancet Digital Health on August 19. The study evaluated the company’s acellular tissue...
🔴 Humacyte falls 5.4% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Humacyte is trading 8.82% down in pre-market; no new company-specific news found
Humacyte is trading 8.82% down at $0.67 in pre-market, with no new company-specific announcement, filing, earnings release, or analyst action found to explain...
Humacyte's Lancet-Published Trial Beat Standard Dialysis Care — But Can a $0.65 Stock Survive Long Enough to Cash In?
Shares of Humacyte surged 11.5% to $0.65 on August 19 after The Lancet Digital Health published one-year results from the company's pivotal Phase 3...
🟢 Humacyte is trading 11.5% up today after Lancet publication of positive V007 Phase 3 results
Humacyte is trading 11.5% up now at $0.65 after August 19, 2026 publication of one-year V007 Phase 3 results in The Lancet Digital Health. - The peer-reviewed...
🔴 Humacyte is trading 5.8% down today after second-quarter revenue missed expectations
Humacyte is trading 5.8% down now at $0.57 after investors continued reacting to its August 12 second-quarter report, which showed revenue of $406,000 versus...
🟢 Humacyte is trading 11% up today after positive V012 dialysis results and sBLA plans
Humacyte is trading 10.62% up at $0.61 after investors reassessed its August 12 earnings update and positive Phase 3 dialysis results. - V012 showed ATEV...
🟢 Humacyte is trading 5% up today with no confirmed fresh catalyst
Humacyte is trading 5.29% up now at $0.58 after the August 13 selloff, with no confirmed fresh catalyst. - Shares fell 17.29% to $0.55 after the August 12...
🟢 Humacyte is trading 7.27% up in pre-market after positive Phase 3 dialysis results
Humacyte is trading 7.27% up now at $0.59 after investors weighed positive Phase 3 dialysis results and plans to file a supplemental biologics license...
🟢 Humacyte is trading 10.89% up in after-hours trading despite no new company-specific catalyst
Humacyte is trading at $0.61, up 10.89% in after-hours trading, with no new company-specific catalyst identified in available coverage. - Shares declined...
🟢 Humacyte is trading 6.65% up in after-hours trading after positive Phase 3 dialysis data
Humacyte is trading 6.65% up in after-hours trading at $0.59 after releasing second-quarter results and highlighting positive Phase 3 dialysis data. -...
🔴 Humacyte is trading 10.9% down today after missing Q2 revenue and EPS estimates
Humacyte is trading 10.9% down at $0.59 after its August 12, 2026, second-quarter results missed analyst expectations. - EPS was -$0.16 versus -$0.09...
🔴 Humacyte is trading 5% down today after Q2 revenue and EPS missed estimates
Humacyte is trading 5.17% down at $0.63 after its August 12, 2026, second-quarter earnings release showed revenue and EPS misses. - Revenue was $410,000...
🔴 Humacyte is trading 12.68% down today after Q2 results missed estimates
Humacyte is trading 12.68% down now at $0.62 after its August 12, 2026 second-quarter results missed consensus expectations. - Revenue was $410,000 versus...